var data={"title":"Peutz-Jeghers syndrome: Screening and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Peutz-Jeghers syndrome: Screening and management</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/contributors\" class=\"contributor contributor_credentials\">Daniel C Chung, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/contributors\" class=\"contributor contributor_credentials\">Tomer Adar, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/contributors\" class=\"contributor contributor_credentials\">J Thomas Lamont, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/contributors\" class=\"contributor contributor_credentials\">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H87506833\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and extraintestinal cancer. Although polyps most commonly occur in the small bowel, they can be found throughout the gastrointestinal tract, including the stomach and colon.</p><p>This topic will review the management of PJS. The clinical manifestations and diagnosis of PJS and other familial hamartomatous polyposis syndromes and adenomatous polyposis syndromes of the gastrointestinal tract are discussed in detail, separately [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">&quot;Juvenile polyposis syndrome&quot;</a> and <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;</a> and <a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">&quot;Familial adenomatous polyposis: Screening and management of patients and families&quot;</a> and <a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">&quot;MUTYH-associated polyposis&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H87507021\"><span class=\"h1\">MANAGEMENT OF PEUTZ-JEGHERS SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Guidelines for cancer screening in individuals with Peutz-Jeghers syndrome (PJS) have been proposed by several groups and are largely based on expert opinion and limited observational data [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/2-5\" class=\"abstract_t\">2-5</a>]. Our recommendations are largely consistent with the guidelines issued by the American College of Gastroenterology (ACG) and the National Comprehensive Cancer Network (NCCN) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p class=\"headingAnchor\" id=\"H87507394\"><span class=\"h2\">Routine management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with PJS should undergo an annual physical examination with a complete blood count to detect iron deficiency anemia due to occult bleeding from gastrointestinal tract polyps or cancer. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H5\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Hamartomatous polyps'</a> and <a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults#H2\" class=\"medical medical_review\">&quot;Causes and diagnosis of iron deficiency and iron deficiency anemia in adults&quot;, section on 'Causes of iron deficiency'</a>.)</p><p class=\"headingAnchor\" id=\"H166674972\"><span class=\"h2\">Cancer screening</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with PJS are at<strong> </strong>an increased risk of gastrointestinal and extraintestinal cancer. The lifetime risk of cancer ranges between 37 and 93 percent, with an average age of 42 years at cancer diagnosis [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/4\" class=\"abstract_t\">4</a>]. The most common sites of gastrointestinal tract malignancy are the colon and pancreas, and the most common site of extraintestinal tract cancer is the breast. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H3\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Clinical manifestations'</a>.)</p><p class=\"headingAnchor\" id=\"H439359851\"><span class=\"h3\">Gastrointestinal cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Due to the increased risk for gastric, small bowel, and colorectal polyps and cancer in individuals with PJS, baseline endoscopic screening of the gastrointestinal tract should include upper gastrointestinal endoscopy (esophagogastroduodenoscopy), video capsule endoscopy (VCE), and colonoscopy, beginning at age eight years. The subsequent screening interval should be based on the findings at baseline examination:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If polyps are detected on baseline screening, an upper endoscopy, VCE, and colonoscopy should be repeated every three years. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If no polyps are detected on baseline screening, an upper endoscopy, VCE, and colonoscopy should be repeated at age 18 years, or sooner if symptoms arise, and then every three years.</p><p/><p>Magnetic resonance enterography is an alternative imaging modality for individuals with PJS in whom capsule endoscopy cannot be performed [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/7\" class=\"abstract_t\">7</a>]. While neither methodology is associated with ionizing radiation, magnetic resonance imagining (MRI) may be more accurate in identifying and localizing clinically relevant PJS polyps [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/8\" class=\"abstract_t\">8</a>]. The use of barium follow-through and computed tomography enterography is limited by radiation exposure and should be avoided in children. (See <a href=\"topic.htm?path=wireless-video-capsule-endoscopy#H62241714\" class=\"medical medical_review\">&quot;Wireless video capsule endoscopy&quot;, section on 'Contraindications'</a> and <a href=\"topic.htm?path=radiation-related-risks-of-imaging#H244757\" class=\"medical medical_review\">&quot;Radiation-related risks of imaging&quot;, section on 'Pediatrics'</a>.)</p><p class=\"headingAnchor\" id=\"H522031833\"><span class=\"h4\">Management of gastrointestinal tract polyps</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endoscopic polypectomy should be performed for polyps larger than 0.5 to 1 cm in size in order to reduce the risk of polyp-related complications (eg, anemia, bleeding, obstruction, malignancy, and need for urgent surgery) [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3,5\" class=\"abstract_t\">3,5</a>]. Advances in small bowel endoscopy have improved the ability to treat small bowel polyps without surgery. Successful small bowel polypectomy using balloon-assisted enteroscopy has been described with both single and double balloon enteroscopies [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Endoscopists should be aware of possible challenges in performing double balloon enteroscopy in patients who have had previous abdominal surgery and may have peritoneal adhesions and altered anatomy. Patients with PJS may also be at increased risk for perforation with polypectomy due to serosal invagination within the polyp stalk [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Indications for surgery include the inability to achieve endoscopic polyp control either due to polyp size or number and the presence of neoplasia. Surgery may also be required in patients with small bowel obstruction or intussusception. Patients with PJS undergoing laparotomy should undergo intraoperative enteroscopy to identify and resect small bowel polyps [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=intussusception-in-children#H14\" class=\"medical medical_review\">&quot;Intussusception in children&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=evaluation-of-suspected-small-bowel-bleeding-formerly-obscure-gastrointestinal-bleeding#H9\" class=\"medical medical_review\">&quot;Evaluation of suspected small bowel bleeding (formerly obscure gastrointestinal bleeding)&quot;, section on 'Intraoperative enteroscopy'</a>.)</p><p class=\"headingAnchor\" id=\"H973704632\"><span class=\"h4\">Chemoprevention</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemopreventive approaches to decrease polyp burden in PJS have been studied, but there are insufficient data to recommend their use [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/11\" class=\"abstract_t\">11</a>]. Polyps in PJS overexpress cyclooxygenase-2 (COX-2), suggesting that COX-2 inhibitors may be useful in reducing polyp burden [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/12\" class=\"abstract_t\">12</a>]. In addition, inhibition of mammalian target of rapamycin (MTOR) in a PJS mouse model has also been demonstrated to decrease polyp burden [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/13\" class=\"abstract_t\">13</a>]. </p><p class=\"headingAnchor\" id=\"H439359771\"><span class=\"h3\">Genital tract cancers</span></p><p class=\"headingAnchor\" id=\"H439359795\"><span class=\"h4\">Testicular tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with PJS are at increased risk for Sertoli cell tumors, with a mean age at diagnosis of nine years [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/14,15\" class=\"abstract_t\">14,15</a>]. Annual examinations of the testicles should be performed from birth until teenage years. If abnormalities are detected on testicular examination or if patients have signs of feminization (eg, gynecomastia), a testicular ultrasound should be obtained [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H435867596\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Nongastrointestinal cancers'</a> and <a href=\"topic.htm?path=testicular-sex-cord-stromal-tumors#H2\" class=\"medical medical_review\">&quot;Testicular sex cord stromal tumors&quot;, section on 'Clinical presentation'</a> and <a href=\"topic.htm?path=the-pediatric-physical-examination-the-perineum#H3\" class=\"medical medical_review\">&quot;The pediatric physical examination: The perineum&quot;, section on 'Males'</a>.)</p><p class=\"headingAnchor\" id=\"H439359245\"><span class=\"h4\">Cervical cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Women with PJS are at increased risk for adenoma malignum, a well-differentiated adenocarcinoma of the uterine cervix. We therefore advise women with PJS to undergo annual screening for cervical cancer (including Pap smear) starting at age 21 years. [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H435867596\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Nongastrointestinal cancers'</a> and <a href=\"topic.htm?path=screening-for-cervical-cancer\" class=\"medical medical_review\">&quot;Screening for cervical cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H439359258\"><span class=\"h4\">Ovarian and endometrial cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We screen women with PJS for endometrial and ovarian cancer with an annual pelvic exam and pelvic or transvaginal ultrasound starting at age 21 years [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3-5\" class=\"abstract_t\">3-5</a>]. However, screening for endometrial and ovarian cancer in women with PJS is controversial, and guidelines differ in their recommendations. The NCCN and ACG guidelines recommend screening with pelvic exam and pelvic or transvaginal ultrasound annually between the ages of 18 and 20 years and at age 25 years, respectively [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/5,6\" class=\"abstract_t\">5,6</a>]. However, other expert guidelines do not recommend screening for endometrial cancer, given that most cases of sporadic endometrial cancer are detected at an early stage, the low risk of endometrial cancer in PJS, and the lack of evidence to support screening [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H435867596\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Nongastrointestinal cancers'</a> and <a href=\"topic.htm?path=sex-cord-stromal-tumors-of-the-ovary-tumors-with-granulosa-and-sertoli-leydig-elements\" class=\"medical medical_review\">&quot;Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H87507528\"><span class=\"h3\">Breast cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk for breast cancer in PJS patients approaches that of <em>BRCA</em> mutation carriers [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3\" class=\"abstract_t\">3</a>]. We therefore suggest monthly breast self-examinations for women with PJS starting at age 18 years and annual breast MRI <span class=\"nowrap\">and/or</span> mammography starting at age 25 years [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=screening-for-breast-cancer-evidence-for-effectiveness-and-harms#H3757808\" class=\"medical medical_review\">&quot;Screening for breast cancer: Evidence for effectiveness and harms&quot;, section on 'Effectiveness of imaging studies in breast cancer screening'</a> and <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H435867596\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Nongastrointestinal cancers'</a>.) </p><p class=\"headingAnchor\" id=\"H87507534\"><span class=\"h3\">Pancreatic cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Screening for pancreatic cancer in individuals with PJS should be performed in experienced centers, preferably within an Institutional Review Board (IRB)-approved clinical research study [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3,16\" class=\"abstract_t\">3,16</a>]. Screening for pancreatic cancer should be performed with <span class=\"nowrap\">MRI/magnetic</span> resonance cholangiopancreatography or endoscopic ultrasound of the pancreas every one to two years, beginning at age 30 years [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis#H435867590\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Gastrointestinal cancers'</a> and <a href=\"topic.htm?path=familial-risk-factors-for-pancreatic-cancer-and-screening-of-high-risk-patients#H3097420866\" class=\"medical medical_review\">&quot;Familial risk factors for pancreatic cancer and screening of high-risk patients&quot;, section on 'Pancreatic cancer screening'</a>.)</p><p class=\"headingAnchor\" id=\"H113642493\"><span class=\"h3\">Other malignancies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with PJS are also at an increased risk for thyroid and lung cancer. However, evidence to support routine screening for these cancers in the absence of other risk factors is lacking. Patients should seek medical attention for evaluation of new symptoms and should be strongly counselled to quit smoking [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/2,3,5\" class=\"abstract_t\">2,3,5</a>]. (See <a href=\"topic.htm?path=radiation-induced-thyroid-cancer\" class=\"medical medical_review\">&quot;Radiation-induced thyroid cancer&quot;</a> and <a href=\"topic.htm?path=screening-for-lung-cancer\" class=\"medical medical_review\">&quot;Screening for lung cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H113642551\"><span class=\"h2\">Other issues</span></p><p class=\"headingAnchor\" id=\"H973704699\"><span class=\"h3\">Cutaneous hyperpigmentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 95 percent of PJS patients develop mucocutaneous pigmented macules. While most cutaneous lesions fade with age, lesions that are disfiguring or associated with psychological morbidity may require treatment [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3,17-20\" class=\"abstract_t\">3,17-20</a>]. The management of cutaneous hyperpigmentation is discussed in detail, separately. (See <a href=\"topic.htm?path=acquired-hyperpigmentation-disorders#H664788\" class=\"medical medical_review\">&quot;Acquired hyperpigmentation disorders&quot;, section on 'General principles of treatment'</a> and <a href=\"topic.htm?path=congenital-and-inherited-hyperpigmentation-disorders#H75796009\" class=\"medical medical_review\">&quot;Congenital and inherited hyperpigmentation disorders&quot;, section on 'Peutz-Jeghers syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H87507600\"><span class=\"h3\">Genetic counseling</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PJS is an autosomal dominant disorder, and a child of a PJS parent has a 50 percent chance of inheriting the disease. Individuals with an <em>STK11</em> mutation should be offered the option of a pre-implantation genetic diagnosis during preconception counseling [<a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/21-23\" class=\"abstract_t\">21-23</a>]. However, patients should also be made aware of the limitations and the risks for misdiagnosis. (See <a href=\"topic.htm?path=preimplantation-genetic-testing#H6\" class=\"medical medical_review\">&quot;Preimplantation genetic testing&quot;, section on 'Genetic evaluation'</a>.)</p><p>First-degree relatives of patients with PJS should be screened annually, beginning at birth, for clinical features of PJS. Screening consists of a history and a physical examination that includes evaluation for mucocutaneous pigmentation and signs of precocious puberty. In addition, male patients should be examined for signs of feminization (eg, gynecomastia) and for testicular tumors with testicular palpation. Predictive genetic testing should be offered to at-risk individuals in whom the diagnosis is not already clinically apparent by eight years of age, provided a pathogenic <em>STK11</em> mutation has been identified in an affected family member. The results of genetic testing can then guide future screening recommendations. (See <a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty#H266911694\" class=\"medical medical_review\">&quot;Definition, etiology, and evaluation of precocious puberty&quot;, section on 'Definition'</a> and <a href=\"topic.htm?path=genetic-testing#H4404427\" class=\"medical medical_review\">&quot;Genetic testing&quot;, section on 'Testing children'</a> and <a href=\"topic.htm?path=the-pediatric-physical-examination-the-perineum#H3\" class=\"medical medical_review\">&quot;The pediatric physical examination: The perineum&quot;, section on 'Males'</a>.)</p><p class=\"headingAnchor\" id=\"H3648301914\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hereditary colorectal cancer syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H439359272\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and extraintestinal cancer. (See <a href=\"#H87506833\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The lifetime risk of cancer ranges between 37 and 93 percent, with an average age of 42 years at cancer diagnosis. The most common sites of gastrointestinal tract malignancy are the colon and pancreas, and the most common site of extraintestinal tract cancer is the breast. (See <a href=\"#H87507021\" class=\"local\">'Management of Peutz-Jeghers syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Our approach to cancer screening in individuals with PJS is as follows (see <a href=\"#H87507394\" class=\"local\">'Routine management'</a> above and <a href=\"#H166674972\" class=\"local\">'Cancer screening'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Annual physical examination with a complete blood count to detect iron deficiency anemia due to occult bleeding from gastrointestinal tract polyps or cancer.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Colonoscopy, video capsule endoscopy, and upper gastrointestinal endoscopy initially at age eight years and repeated every three years if polyps are found. If no polyps are detected on baseline screening, an upper endoscopy, video capsule endoscopy, and colonoscopy should be repeated at age 18 years, or sooner if symptoms arise, and every three years thereafter. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Annual examination of the testicles from birth until teenage years. If abnormalities are detected on testicular examination or if patients have signs of feminization (eg, gynecomastia), a testicular ultrasound should be obtained.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Annual pelvic examination with Pap smear and <span class=\"nowrap\">transvaginal/transabdominal</span> ultrasound starting at age 21 years to screen for cervical, endometrial, and ovarian cancer.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Monthly breast self-examinations for women starting at age 18 years and annual breast magnetic resonance imaging <span class=\"nowrap\">and/or</span> annual mammography starting at age 25 years.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Magnetic resonance <span class=\"nowrap\">imaging/magnetic</span> resonance cholangiopancreatography or endoscopic ultrasound of the pancreas every one to two years, beginning at age 30, to screen for pancreatic cancer. Screening for pancreatic cancer should only be performed at centers of expertise in the setting of a research protocol.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals with an <em>STK11</em> mutation should be offered the option of a pre-implantation genetic diagnosis during preconception counseling. First-degree relatives of patients with PJS should be screened beginning at birth for clinical features of PJS. Screening consists of an annual history, a physical examination that includes evaluation for mucocutaneous pigmentation, and signs of precocious puberty. In addition, male patients should be examined for signs of feminization (eg, gynecomastia) and for testicular tumors with testicular palpation. Predictive genetic testing should be offered to at-risk individuals in whom the diagnosis is not already clinically apparent by age eight years, provided a pathogenic <em>STK11</em> mutation has been identified in an affected family member. (See <a href=\"#H87507600\" class=\"local\">'Genetic counseling'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1216463346\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Peter Bonis, MD, Dennis Ahnen, MD, and Lisen Axell, MS, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/1\" class=\"nounderline abstract_t\">Harned RK, Buck JL, Sobin LH. The hamartomatous polyposis syndromes: clinical and radiologic features. AJR Am J Roentgenol 1995; 164:565.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/2\" class=\"nounderline abstract_t\">Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128:896.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/3\" class=\"nounderline abstract_t\">Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59:975.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/4\" class=\"nounderline abstract_t\">van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105:1258.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/5\" class=\"nounderline abstract_t\">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li><li class=\"breakAll\">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic/Familial High Risk Assessment: Colorectal. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on November 13, 2015).</li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/7\" class=\"nounderline abstract_t\">Gupta A, Postgate AJ, Burling D, et al. A prospective study of MR enterography versus capsule endoscopy for the surveillance of adult patients with Peutz-Jeghers syndrome. AJR Am J Roentgenol 2010; 195:108.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/8\" class=\"nounderline abstract_t\">Tomas C, Soyer P, Dohan A, et al. Update on imaging of Peutz-Jeghers syndrome. World J Gastroenterol 2014; 20:10864.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/9\" class=\"nounderline abstract_t\">Korsse SE, Dewint P, Kuipers EJ, van Leerdam ME. Small bowel endoscopy and Peutz-Jeghers syndrome. Best Pract Res Clin Gastroenterol 2012; 26:263.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/10\" class=\"nounderline abstract_t\">Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004; 39:219.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/11\" class=\"nounderline abstract_t\">Kuwada SK, Burt R. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome. Fam Cancer 2011; 10:469.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/12\" class=\"nounderline abstract_t\">Udd L, Katajisto P, Rossi DJ, et al. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 2004; 127:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/13\" class=\"nounderline abstract_t\">Wei C, Amos CI, Zhang N, et al. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 2008; 14:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/14\" class=\"nounderline abstract_t\">Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4:408.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/15\" class=\"nounderline abstract_t\">Dreyer L, Jacyk WK, du Plessis DJ. Bilateral large-cell calcifying Sertoli cell tumor of the testes with Peutz-Jeghers syndrome: a case report. Pediatr Dermatol 1994; 11:335.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/16\" class=\"nounderline abstract_t\">Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62:339.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/17\" class=\"nounderline abstract_t\">Li Y, Tong X, Yang J, et al. Q-switched alexandrite laser treatment of facial and labial lentigines associated with Peutz-Jeghers syndrome. Photodermatol Photoimmunol Photomed 2012; 28:196.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/18\" class=\"nounderline abstract_t\">Xi Z, Hui Q, Zhong L. Q-switched alexandrite laser treatment of oral labial lentigines in Chinese subjects with Peutz-Jeghers syndrome. Dermatol Surg 2009; 35:1084.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/19\" class=\"nounderline abstract_t\">Chang CJ, Nelson JS. Q-switched ruby laser treatment of mucocutaneous melanosis associated with Peutz-Jeghers syndrome. Ann Plast Surg 1996; 36:394.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/20\" class=\"nounderline abstract_t\">Benedict LM, Cohen B. Treatment of Peutz-Jeghers lentigines with the carbon dioxide laser. J Dermatol Surg Oncol 1991; 17:954.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/21\" class=\"nounderline abstract_t\">Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Preimplantation genetic testing: a Practice Committee opinion. Fertil Steril 2007; 88:1497.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/22\" class=\"nounderline abstract_t\">van Lier MG, Korsse SE, Mathus-Vliegen EM, et al. Peutz-Jeghers syndrome and family planning: the attitude towards prenatal diagnosis and pre-implantation genetic diagnosis. Eur J Hum Genet 2012; 20:236.</a></li><li><a href=\"https://www.uptodate.com/contents/peutz-jeghers-syndrome-screening-and-management/abstract/23\" class=\"nounderline abstract_t\">Woo A, Sadana A, Mauger DT, et al. Psychosocial impact of Peutz-Jeghers Syndrome. Fam Cancer 2009; 8:59.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 103580 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H439359272\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H87506833\" id=\"outline-link-H87506833\">INTRODUCTION</a></li><li><a href=\"#H87507021\" id=\"outline-link-H87507021\">MANAGEMENT OF PEUTZ-JEGHERS SYNDROME</a><ul><li><a href=\"#H87507394\" id=\"outline-link-H87507394\">Routine management</a></li><li><a href=\"#H166674972\" id=\"outline-link-H166674972\">Cancer screening</a><ul><li><a href=\"#H439359851\" id=\"outline-link-H439359851\">- Gastrointestinal cancer</a><ul><li><a href=\"#H522031833\" id=\"outline-link-H522031833\">Management of gastrointestinal tract polyps</a></li><li><a href=\"#H973704632\" id=\"outline-link-H973704632\">Chemoprevention</a></li></ul></li><li><a href=\"#H439359771\" id=\"outline-link-H439359771\">- Genital tract cancers</a><ul><li><a href=\"#H439359795\" id=\"outline-link-H439359795\">Testicular tumors</a></li><li><a href=\"#H439359245\" id=\"outline-link-H439359245\">Cervical cancer</a></li><li><a href=\"#H439359258\" id=\"outline-link-H439359258\">Ovarian and endometrial cancer</a></li></ul></li><li><a href=\"#H87507528\" id=\"outline-link-H87507528\">- Breast cancer</a></li><li><a href=\"#H87507534\" id=\"outline-link-H87507534\">- Pancreatic cancer</a></li><li><a href=\"#H113642493\" id=\"outline-link-H113642493\">- Other malignancies</a></li></ul></li><li><a href=\"#H113642551\" id=\"outline-link-H113642551\">Other issues</a><ul><li><a href=\"#H973704699\" id=\"outline-link-H973704699\">- Cutaneous hyperpigmentation</a></li><li><a href=\"#H87507600\" id=\"outline-link-H87507600\">- Genetic counseling</a></li></ul></li></ul></li><li><a href=\"#H3648301914\" id=\"outline-link-H3648301914\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H439359272\" id=\"outline-link-H439359272\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1216463346\" id=\"outline-link-H1216463346\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-hyperpigmentation-disorders\" class=\"medical medical_review\">Acquired hyperpigmentation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Causes and diagnosis of iron deficiency and iron deficiency anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of familial adenomatous polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-and-inherited-hyperpigmentation-disorders\" class=\"medical medical_review\">Congenital and inherited hyperpigmentation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-etiology-and-evaluation-of-precocious-puberty\" class=\"medical medical_review\">Definition, etiology, and evaluation of precocious puberty</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-suspected-small-bowel-bleeding-formerly-obscure-gastrointestinal-bleeding\" class=\"medical medical_review\">Evaluation of suspected small bowel bleeding (formerly obscure gastrointestinal bleeding)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-adenomatous-polyposis-screening-and-management-of-patients-and-families\" class=\"medical medical_review\">Familial adenomatous polyposis: Screening and management of patients and families</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-risk-factors-for-pancreatic-cancer-and-screening-of-high-risk-patients\" class=\"medical medical_review\">Familial risk factors for pancreatic cancer and screening of high-risk patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-testing\" class=\"medical medical_review\">Genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intussusception-in-children\" class=\"medical medical_review\">Intussusception in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=juvenile-polyposis-syndrome\" class=\"medical medical_review\">Juvenile polyposis syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">MUTYH-associated polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">PTEN hamartoma tumor syndrome, including Cowden syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preimplantation-genetic-testing\" class=\"medical medical_review\">Preimplantation genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-induced-thyroid-cancer\" class=\"medical medical_review\">Radiation-induced thyroid cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-related-risks-of-imaging\" class=\"medical medical_review\">Radiation-related risks of imaging</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-for-breast-cancer-evidence-for-effectiveness-and-harms\" class=\"medical medical_review\">Screening for breast cancer: Evidence for effectiveness and harms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-for-cervical-cancer\" class=\"medical medical_review\">Screening for cervical cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-for-lung-cancer\" class=\"medical medical_review\">Screening for lung cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sex-cord-stromal-tumors-of-the-ovary-tumors-with-granulosa-and-sertoli-leydig-elements\" class=\"medical medical_review\">Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">Society guideline links: Hereditary colorectal cancer syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=testicular-sex-cord-stromal-tumors\" class=\"medical medical_review\">Testicular sex cord stromal tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-pediatric-physical-examination-the-perineum\" class=\"medical medical_review\">The pediatric physical examination: The perineum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=wireless-video-capsule-endoscopy\" class=\"medical medical_review\">Wireless video capsule endoscopy</a></li></ul></div></div>","javascript":null}